Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study.
2016 ◽
Vol 34
(15_suppl)
◽
pp. 1074-1074
Keyword(s):
Phase 2
◽